Double Unrelated Reduced-Intensity Umbilical Cord Blood Transplantation in Adults

Biology of Blood and Marrow Transplantation

Volumn 13, Issue 1, 2007, Pages 82-89

  Ballen, Karen K ^a   Spitzer, Thomas R ^a   Yeap, Beow Y ^a   McAfee, Steven ^a   Dey, Bimalangshu R ^a   Attar, Eyal ^a   Haspel, Richard ^a   Kao, Grace ^b   Liney, Deborah ^b   Alyea, Edwin ^b   Lee, Stephanie ^b   Cutler, Corey ^b   Ho, Vincent ^b   Soiffer, Robert ^b   Antin, Joseph H ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; CYCLOSPORIN; FLUDARABINE; MELPHALAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ARTICLE; CELL NUCLEUS; CHIMERA; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; CORD BLOOD STEM CELL TRANSPLANTATION; CRYOPRESERVATION; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; GRAFT FAILURE; HEMATOLOGIC MALIGNANCY; HLA MATCHING; HUMAN; MALE; NEUTROPHIL COUNT; SURVIVAL RATE; THROMBOCYTE COUNT;

ADULT; ANTILYMPHOCYTE SERUM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CORD BLOOD STEM CELL TRANSPLANTATION; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HISTOCOMPATIBILITY TESTING; HUMANS; MALE; MELPHALAN; MIDDLE AGED; SURVIVAL ANALYSIS; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING; VIDARABINE;

EID: 33846007695     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2006.08.041     Document Type: Article

References (32)

1. Broxmeyer H.E., Douglas G.W., Hangoc G., et al. Human umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitor cells. Proc Natl Acad Sci USA 86 (1989) 3828-3832
2. Kurtzberg J., Laughlin M., Graham M.L., et al. Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N Engl J Med 335 (1996) 157-166
3. Wagner J.E., Barker J.N., DeFor T.E., et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood 100 (2002) 1611-1618
4. Michel G., Rocha V., Chevret S., et al. Unrelated cord blood transplantation for childhood acute myeloid leukemia: a Eurocord Group analysis. Blood 102 (2003) 4290-4297
5. Ballen K.K. New trends in umbilical cord blood transplantation. Blood 105 (2005) 3786-3792
6. Laughlin M.J., Barker J., Bambach B., et al. Hematopoietic engraftment and survival in adult recipients of umbilical cord blood from unrelated donors. N Engl J Med 344 (2001) 1815-1822
7. Long G.D., Laughlin M., Madan B., et al. Unrelated umbilical cord blood transplantation in adult patients. Biol Blood Marrow Transplant 9 (2003) 772-780
8. Rubinstein P., Carrier C., Scaradavou A., et al. Outcomes among 562 recipients of placental blood transplants from unrelated donors. N Engl J Med 339 (1998) 1565-1577
9. Barker J.N., Weisdorf D.J., DeFor T.E., et al. Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning. Blood 102 (2003) 1915-1919
10. Barker J.N., Weisdorf D.J., DeFor T.E., et al. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood 105 (2005) 1343-1347
11. Verneris M.R., Brunstein C., DeFor T.E., et al. Risk of relapse after umbilical cord blood transplantation in patients with acute leukemia: marked reduction in recipients of two units. [abstract]. Blood 106 (2005) 305a
12. Rubinstein P., Dobrila L., Rosenfield R.E., et al. Processing and cryopreservation of placental/umbilical cord blood for unrelated bone marrow reconstitution. Proc Natl Acad Sci USA 92 (1995) 10119-10122
13. Przepiorka D., Weisdorf D., Martin P., et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant 15 (1995) 825-828
14. Schichman S.A., Suess P., Vertino A.M., et al. Comparison of short tandem repeat and variable-number tandem repeat genetic markers for quantitative determination of allogeneic bone marrow transplant engraftment. Bone Marrow Transplant 29 (2002) 243-248
15. Sykes M., Preffer F., McAfee S., et al. Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone marrow transplantation. Lancet 353 (1999) 1755-1759
16. Giralt S., Thall P.F., Khouri I., et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 97 (2001) 631-637
17. Chakraverty R., Peggs K., Chopra R., et al. Limiting TRM following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood 99 (2002) 1071-1078
18. Koh L.P., and Chao N.J. Umbilical cord blood transplantation in adults using myeloablative and nonmyeloablative preparative regimens. Biol Blood Marrow Transplant 10 (2004) 1-22
19. Yuji K., Miyakoshi S., Kato D., et al. Reduced-intensity unrelated cord blood transplantation for patients with advanced malignant lymphoma. Biol Blood Marrow Transplant 11 (2005) 314-318
20. Locatelli F., Rocha V., Chastang C., et al., Eurocord Cord Blood Transplant Group. Factors associated with outcome after cord blood transplantation in children with acute leukemia. Blood 93 (1999) 3662-3671
21. Weinreb S., Delgado J.C., Clavijo O.P., et al. Transplantation of unrelated cord blood cells. Bone Marrow Transplant 22 (1998) 193-196
22. Ballen K.K., Becker P.S., Emmons R.V., et al. Low-dose total body irradiation followed by allogeneic lymphocyte infusion may induce remission in patients with refractory hematologic malignancy. Blood 100 (2002) 442-450
23. Alyea E.P., Kim T.H., Ho V., et al. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood 105 (2005) 1810-1814
24. Brunstein C.G., Weisdorf D.J., DeFor T., et al. Increased risk of Epstein-Barr virus-associated post-transplant lymphoproliferative disorder (EBV-PTLD) after anti-thymocyte globulin non-myeloablative conditioning for umbilical cord blood transplantation. [abstract]. Blood 106 (2005) 3235a
25. Haspel R.L., Kao G.S., Yeap B., et al. Pre-infusion characteristics of the predominant cord blood unit correlate with hematopoietic engraftment in the setting of non- myeloablative double cord blood transplant. [abstract]. Blood 106 (2005) 3027a
26. Calvi L.M., Adams G.B., Weibrecht K.W., et al. Osteoblastic cells regulate the hematopoietic stem cell niche. Nature 425 (2003) 841-846
27. Stier S., Ko Y., Forkert R., et al. Osteopontin is a hematopoietic stem cell niche component that negatively regulates stem cell pool size. J Exp Med 201 (2005) 1781-1791
28. Nilsson S.K., Johnson H.M., Coverdale J.A., et al. Spatial localization of transplanted hemopoietic stem cells: inferences for the localization of stem cell niches. Blood 97 (2001) 2293-2299
29. Barker J.N., Scaradavou A., Stevens C.E., et al. Analysis of 608 umbilical cord blood transplants. HLA match is a critical determinant of transplant-related mortality in the post-engraftment period even in the absence of graft-vs-host disease. [abstract]. Blood 106 (2005) 303a
30. Flomenberg N., Baxter-Lowe L.A., Confer D., et al. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation. HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood 104 (2004) 1923-1930
31. Ho V.T., Kim H.T., Liney D., et al. HLA-C mismatch is associated with inferior survival after unrelated donor non-myeloablative hematopoietic stem cell transplantation. Bone Marrow Transplant 37 (2006) 845-850
32. Kogler G., Enczmann J., Rocha V., et al. High-resolution HLA typing by sequencing for HLA-A, -B, -C, -DR, and -DQ in 122 unrelated cord blood/patient pair transplants hardly improves long-term clinical outcome. Bone Marrow Transplant 36 (2005) 1033-1041